Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Other financing activities: 2010-2018

Historic Other financing activities for Vanda Pharmaceuticals (VNDA) over the last 5 years, with Mar 2018 value amounting to $2.7 million.

  • Vanda Pharmaceuticals' Other financing activities rose 20.69% to $2.7 million in Q1 2018 from the same period last year, while for Mar 2018 it was $5.7 million, marking a year-over-year decrease of 42.55%. This contributed to the annual value of $5.3 million for FY2017, which is 32.25% down from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Other financing activities of $2.7 million as of Q1 2018, which was up 3,191.36% from $81,000 recorded in Q4 2017.
  • Over the past 5 years, Vanda Pharmaceuticals' Other financing activities peaked at $5.9 million during Q3 2016, and registered a low of $24,000 during Q1 2016.
  • In the last 3 years, Vanda Pharmaceuticals' Other financing activities had a median value of $1.1 million in 2016 and averaged $1.7 million.
  • Examining YoY changes over the last 5 years, Vanda Pharmaceuticals' Other financing activities showed a top increase of 122,300.00% in 2014 and a maximum decrease of 95.97% in 2014.
  • Quarterly analysis of 5 years shows Vanda Pharmaceuticals' Other financing activities stood at $174,000 in 2014, then soared by 1,707.58% to $3.6 million in 2015, then soared by 63.82% to $750,000 in 2016, then plummeted by 89.20% to $81,000 in 2017, then rose by 20.69% to $2.7 million in 2018.
  • Its Other financing activities stands at $2.7 million for Q1 2018, versus $81,000 for Q4 2017 and $768,000 for Q3 2017.